Staci Martin Selected Research

Farnesyltranstransferase (Farnesyltransferase)

5/2014

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Staci Martin Research Topics

Disease

12	Neoplasms (Cancer) 10/2023 - 03/2013
11	Neurofibromatosis 1 (Neurofibromatosis Type I) 11/2023 - 03/2013
10	Plexiform Neurofibroma 10/2023 - 03/2013
4	Pain (Aches) 11/2023 - 09/2015
3	Neurofibromatoses (Neurofibromatosis) 11/2023 - 12/2016
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 01/2018
2	Schwannomatosis 11/2023 - 01/2018
2	Neurofibromatosis 2 (Neurofibromatosis Type II) 11/2023 - 01/2018
2	Brain Stem Neoplasms (Brain Stem Tumor) 01/2023 - 12/2018
2	Diffuse Intrinsic Pontine Glioma 01/2023 - 12/2018
2	Glioma (Gliomas) 01/2023 - 01/2018
2	Cytokine Release Syndrome 01/2022 - 09/2018
2	Leukemia 01/2022 - 01/2018
2	Sickle Cell Anemia (Hemoglobin S Disease) 01/2021 - 01/2019
2	Nausea 01/2020 - 09/2014
2	Vomiting 01/2020 - 09/2014
2	Exanthema (Rash) 01/2020 - 12/2016
2	Disease Progression 01/2020 - 12/2018
1	Cancer Pain 11/2022
1	Lymphoma (Lymphomas) 11/2020
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 10/2020
1	Paronychia 01/2020
1	Nerve Sheath Neoplasms (Nerve Sheath Neoplasm) 01/2020
1	Diarrhea 01/2020
1	Proteus Syndrome 01/2019
1	Lethargy 12/2018
1	Hallucinations (Hallucination) 09/2018
1	Inflammation (Inflammations) 09/2018
1	Neurilemmoma (Schwannoma) 01/2018
1	Musculoskeletal Abnormalities 01/2018
1	Legius syndrome 01/2018
1	Neurofibroma 12/2016
1	Idiopathic Pulmonary Fibrosis 09/2014

Drug/Important Bio-Agent (IBA)

7	AZD 6244IBA 10/2023 - 12/2016
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2022 - 12/2016
3	CytokinesIBA 01/2022 - 09/2018
2	Uvitex SWN (SWN)IBA 11/2023 - 01/2018
2	dipinacoline glutamateIBA 01/2023 - 12/2018
2	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2018
2	Creatine Kinase (Creatine Phosphokinase)IBA 01/2020 - 12/2016
1	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2021
1	Rituximab (Mabthera)FDA Link 11/2020
1	Methotrexate (Mexate)FDA LinkGeneric 11/2020
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 10/2020
1	MiransertibIBA 01/2019
1	Opioid Analgesics (Opioids)IBA 01/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2018
1	Interleukin-13IBA 12/2018
1	Interleukin-13 Receptors (Interleukin 13 Receptor)IBA 12/2018
1	IL13-PE38IBA 12/2018
1	ExotoxinsIBA 12/2018
1	N-acetylaspartate (N-acetyl aspartate)IBA 12/2018
1	AntigensIBA 01/2018
1	Neurofibromin 1 (Neurofibromin)IBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 12/2016
1	pirfenidoneIBA 09/2014
1	CollagenIBA 09/2014
1	Farnesyltranstransferase (Farnesyltransferase)IBA 05/2014
1	tipifarnib (R115777)IBA 05/2014
1	Sorafenib (BAY 43-9006)FDA Link 03/2013

Therapy/Procedure

8	Therapeutics 11/2022 - 09/2015
2	Immunotherapy 10/2020 - 01/2018
1	Radiotherapy 01/2023
1	Art Therapy 01/2020